205 related articles for article (PubMed ID: 38413637)
1. Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study.
Amer SA; Al-Zahrani A; Imam EA; Ishteiwy EM; Djelleb IF; Abdullh LR; Ballaj D; Amer YA; El-Sokkary RH; Elshabrawy AM; Eskander G; Shah J; Raza ML; ALsafa AMAA; Ali HT; Fawzy HM
Sci Rep; 2024 Feb; 14(1):4785. PubMed ID: 38413637
[TBL] [Abstract][Full Text] [Related]
2. Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.
Alkhalifah JM; Al Seraihi A; Al-Tawfiq JA; Alshehri BF; Alhaluli AH; Alsulais NM; Alessa MM; Seddiq W; Aljeri T; Qahtani MH; Barry M; Al-Otaiby M
Front Public Health; 2023; 11():1043696. PubMed ID: 36908451
[TBL] [Abstract][Full Text] [Related]
3. Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
Cheng Y; Li T; Zheng Y; Xu B; Bi Y; Hu Y; Zhou YH
Hum Vaccin Immunother; 2022 Nov; 18(5):2064134. PubMed ID: 35452357
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects following COVID-19 vaccination in Iran.
Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.
Watanabe A; Kani R; Iwagami M; Takagi H; Yasuhara J; Kuno T
JAMA Pediatr; 2023 Apr; 177(4):384-394. PubMed ID: 36689319
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events.
Pergent M; Haerynck F; Hoste L; Gardulf A
Front Immunol; 2023; 14():1166198. PubMed ID: 37143673
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia.
Alwafi H; Naser AY; Aldhahir AM; Alhazmi A; Alosaimi AN; Mandili RA; Majeed Z; Salawati E; Ekram R; Samannodi M; Assaggaf H; Almatrafi M; Alqahtani JS; Alsanosi SM; Minshawi F
BMC Infect Dis; 2022 Dec; 22(1):911. PubMed ID: 36474174
[TBL] [Abstract][Full Text] [Related]
10. Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.
Zhang S; Li J; Xu R; Chen Q; Sun G; Lin Y; Cao Y; Chen Y; Geng C; Teng Y; Nie J; Li X; Xu G; Liu X; Jin F; Fan Z; Luo T; Liu H; Wang FS; Jiang Z
JMIR Public Health Surveill; 2023 Dec; 9():e46009. PubMed ID: 38060302
[TBL] [Abstract][Full Text] [Related]
11. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q; Li F; Tian J; Kang J; He J
Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of short-term adverse events of COVID-19 vaccines: An observational study.
Fathi F; Ameri A; Safa O; Hassaniazad M; Fathalipour M
Medicine (Baltimore); 2024 Feb; 103(8):e35549. PubMed ID: 38394514
[TBL] [Abstract][Full Text] [Related]
13. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
Front Public Health; 2022; 10():975781. PubMed ID: 36238255
[TBL] [Abstract][Full Text] [Related]
14. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
17. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
18. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia.
Alharbi NK; Al-Tawfiq JA; Alghnam S; Alwehaibe A; Alasmari A; Alsagaby SA; Alsubaie F; Alshomrani M; Farahat FM; Bosaeed M; Alharbi A; Aldibasi O; Assiri AM
J Infect Public Health; 2022 May; 15(5):573-577. PubMed ID: 35472755
[TBL] [Abstract][Full Text] [Related]
20. Rheumatologists' knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey.
Fathi HM; Gazzar IIE; Elazeem MIA; AboulKheir E; Gamal NM; Ismail F; Shereef RRE; Tharwat S; Elwan S; Samy N; Baki NA; Elsaid NY; El-Bahnasawy AS; Moshrif A; Fattah YA; Amer MA; Ibrahim ME; Khalil NM; El-Dessouki S; Abaza N; El-Shanawany AT; Mohamed EF; El-Ghobashy N; Ayoub N; Hammam O; Fawzy S; Sayed S; Gheita TA; Hammam N;
Rheumatol Int; 2022 Jun; 42(6):989-998. PubMed ID: 35429291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
